SCHEMBL24630643

SCHEMBL24630643

COCCn1c(C(C)C)cc2ccc(C(C)(C)C)cc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CASR P41180 4/20 0.38
▸ CCR9 P51686 6/20 0.38
▸ HPGD P15428 1/20 0.37
▸ CACNA1B Q00975 1/20 0.34
▸ PTGER4 P35408 1/20 0.34
▸ AAK1 Q2M2I8 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ ACSS2 Q9NR19 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ LYN P07948 1/20 0.33
▸ SRC P12931 1/20 0.33
▸ BTK Q06187 1/20 0.33
▸ CNR2 P34972 1/20 0.33
▸ NSD2 O96028 1/20 0.33
▸ IDO1 P14902 1/20 0.33
▸ CRHBP P24387 1/20 0.33
▸ TDO2 P48775 1/20 0.33
▸ CASP7 P55210 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24943811 0.82 CCR9 (0.38) CASRCCR9HPGDCACNA1BPTGER4
SCHEMBL24943790 0.81 CCR9 (0.39) CCR9HPGDALDH1A1MAPTSMN1; SMN2
SCHEMBL24943615 0.80 CCR9 (0.38) CCR9
SCHEMBL21341338 0.80 CCR9 (0.40) CCR9HPGDALDH1A1
SCHEMBL24943301 0.76 KCNH2 (0.39) CCR9HPGDALDH1A1MAPTSMN1; SMN2
SCHEMBL24944394 0.73 CASR (0.46) CASR
SCHEMBL12745369 0.72 DNMT1 (0.36) CCR9HPGDCACNA1BALDH1A1ACSS2
SCHEMBL31735708 0.72 PRKCI (0.38) CASRHPGDCACNA1BPTGER4AAK1
SCHEMBL21341730 0.72 KCNH2 (0.35) CASRCCR9HPGDALDH1A1MAPT
SCHEMBL25037435 0.71 MCL1 (0.53) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220378743-A1 METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) 2022-12-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220378743-A1 METHOD FOR TREATING FATTY LIVER DISEASE AND/OR STEATOHEPATITIS SLC10A1, CYP7A1, FABP1 CASR 3327/4885CCR9 2594/4885HPGD 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback